H. Ab, N., Azzazi, M., El Salakawy, W., Saweris, J. (2022). Clinical Outcomes for Patients with Acute Myeloid Leukemia Harboring IDH1 Mutation After Intensive Chemotherapy. The Egyptian Journal of Hospital Medicine, 88(1), 3089-3093. doi: 10.21608/ejhm.2022.244546
Nour El Hoda H. Ab; Mohamed O. Azzazi; Walaa A. El Salakawy; John A. Saweris. "Clinical Outcomes for Patients with Acute Myeloid Leukemia Harboring IDH1 Mutation After Intensive Chemotherapy". The Egyptian Journal of Hospital Medicine, 88, 1, 2022, 3089-3093. doi: 10.21608/ejhm.2022.244546
H. Ab, N., Azzazi, M., El Salakawy, W., Saweris, J. (2022). 'Clinical Outcomes for Patients with Acute Myeloid Leukemia Harboring IDH1 Mutation After Intensive Chemotherapy', The Egyptian Journal of Hospital Medicine, 88(1), pp. 3089-3093. doi: 10.21608/ejhm.2022.244546
H. Ab, N., Azzazi, M., El Salakawy, W., Saweris, J. Clinical Outcomes for Patients with Acute Myeloid Leukemia Harboring IDH1 Mutation After Intensive Chemotherapy. The Egyptian Journal of Hospital Medicine, 2022; 88(1): 3089-3093. doi: 10.21608/ejhm.2022.244546
Clinical Outcomes for Patients with Acute Myeloid Leukemia Harboring IDH1 Mutation After Intensive Chemotherapy
Background: Acute myeloid leukemia (AML) is heterogeneous myeloid disorder with multifactorial pathogenic mechanisms and a broad range of prognosis. AML is characterized by clonal proliferation of poorly differentiated cells of the myeloid lineage. Objective: This study aimed to detect Isocitrate Dehydrogenase 1 (IDH1) mutation in adult Egyptian AML patients and to find correlation between the mutation and prognosis & survival in those patients after intensive chemotherapy. Patients and Methods: Our study included 98 subjects with newly diagnosed AML. They all presented to Ain Shams University Hospital (Hematology Unit). All Patients included in the study were subjected to: History taking and clinical examination, laboratory investigations including routine investigations and cytogenetic studies for detection of IDH 1 mutation. All patients were followed up for their response to treatment for a period of 6 months. Results: IDH1 mutation occurs in a considerable percentage of Egyptian AML patients that shows independent bad prognostic impact on the clinical outcome. Conclusion: IDH1 mutation occurred in a considerable percentage of Egyptian AML patients that showed independent bad prognostic impact on the clinical outcome.